tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Frassetto LA et al. Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients. 2014 Transplantation pmid:24389906
Fung JJ Tacrolimus and transplantation: a decade in review. 2004 Transplantation pmid:15201685
Kee TY et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. 2006 Transplantation pmid:16861939
Pascual J et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. 2006 Transplantation pmid:16861942
Sawabe T et al. Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. 1997 Transplantation pmid:9233725
Heeckt PF et al. Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. 1995 Transplantation pmid:7530870
Drachenberg CB et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. 1999 Transplantation pmid:10459544
van Hooff JP et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. 2003 Transplantation pmid:12829890
Heffron TG et al. Pediatric liver transplantation with daclizumab induction. 2003 Transplantation pmid:12829908
Gonwa T et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. 2003 Transplantation pmid:12829910
Shihab FS et al. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. 1997 Transplantation pmid:9422427
Vu MD et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. 1997 Transplantation pmid:9422432
Shapiro R et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. 1995 Transplantation pmid:7533343
Cox KL et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. 1995 Transplantation pmid:7533344
Oz HS et al. Provocative effects of the immunosuppressants rapamycin, tacrolimus, and dexamethasone on pneumonitis in contrast to the anti- pneumonitis effects of mycophenolate mofetil. 2001 Transplantation pmid:11685124
Staatz CE et al. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. 2001 Transplantation pmid:11579300
Selzner N et al. Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience. 2001 Transplantation pmid:11579301
Fisher NC et al. Chronic renal failure following liver transplantation: a retrospective analysis. 1998 Transplantation pmid:9679823
Tsuchiya T et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. 2013 Transplantation pmid:23792649
Newell KA et al. Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. 1997 Transplantation pmid:9381541
Singh N et al. Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. 1996 Transplantation pmid:8610349
Yanchar NL et al. Tacrolimus (FK506)--its effects on intestinal glucose transport. 1996 Transplantation pmid:8610392
Shapiro R et al. Posttransplant diabetes in pediatric recipients on tacrolimus. 1999 Transplantation pmid:10096540
Hilbrands R et al. Predictive factors of allosensitization after immunosuppressant withdrawal in recipients of long-term cultured islet cell grafts. 2013 Transplantation pmid:23857001
Kihm LP et al. Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography. 2012 Transplantation pmid:22470107
Hoogtanders K et al. Dried blood spot measurement of tacrolimus is promising for patient monitoring. 2007 Transplantation pmid:17264824
Ahuja M et al. Polyoma virus infection after renal transplantation. Use of immunostaining as a guide to diagnosis. 2001 Transplantation pmid:11349723
Pérgola PE et al. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. 2001 Transplantation pmid:11349738
Mestres J et al. Late subcapsular lymphocele in a kidney graft. 2012 Transplantation pmid:22487814
Cherikh WS et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. 2003 Transplantation pmid:14627905
Neumann UP et al. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. 2001 Transplantation pmid:11374419
Xie Y et al. Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. 2017 Transplantation pmid:28187014
Rajesh KG et al. Mitochondrial permeability transition-pore inhibition enhances functional recovery after long-time hypothermic heart preservation. 2003 Transplantation pmid:14627909
Sato T et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. 2003 Transplantation pmid:14627910
Vignali D et al. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody. 2016 Transplantation pmid:27306531
Chakrabarti P et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. 2000 Transplantation pmid:11003353
Arroyo Hornero R et al. CD45RA Distinguishes CD4+CD25+CD127-/low TSDR Demethylated Regulatory T Cell Subpopulations With Differential Stability and Susceptibility to Tacrolimus-Mediated Inhibition of Suppression. 2017 Transplantation pmid:28118317
Tan HP et al. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. 2008 Transplantation pmid:19104412
de Fijter JW Tacrolimus dosing in mycophenolate-treated patients--can we get away with less? 2011 Transplantation pmid:21654351
Rodriguez Rilo HL et al. Rapid hair regrowth in refractory alopecia universalis associated with autoimmune disease following liver transplantation and tacrolimus (FK506) therapy. 1995 Transplantation pmid:7539169
Yamani MH et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. 2000 Transplantation pmid:10868634
Blakolmer K et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. 2000 Transplantation pmid:10868635
Verleden GM et al. Successful conversion from cyclosporine to tacrolimus for gastric motor dysfunction in a lung transplant recipient. 2002 Transplantation pmid:12131703
Johnson C et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. 2000 Transplantation pmid:10755536
Miller J et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. 2000 Transplantation pmid:10755543
Ciancio G et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. 2004 Transplantation pmid:14742989
Hoerning A et al. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. 2015 Transplantation pmid:25099702
Ekberg H et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. 2011 Transplantation pmid:21562449
Yoshimura N et al. A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). 1996 Transplantation pmid:8633388